GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1864, Issue 9, 2018, Pages 2814-2821

  Rizzo, Manfredi ^a,b   Nikolic, Dragana ^a   Patti, Angelo Maria ^a   Mannina, Carlo ^a   Montalto, Giuseppe ^a   McAdams, Brooke S ^b   Rizvi, Ali A ^b   Cosentino, Francesco ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiometabolic parameters; Cardiovascular risk; Glucagon like peptide 1 receptor agonists; Type 2 diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; SEMAGLUTIDE;

ATHEROSCLEROTIC PLAQUE; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CLINICAL OUTCOME; DISEASE EXACERBATION; DRUG EFFECT; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; AGONISTS; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; GLUCOSE BLOOD LEVEL; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; LIRAGLUTIDE; PLAQUE, ATHEROSCLEROTIC;

EID: 85047739558     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2018.05.012     Document Type: Review

References (83)

1. Rizzo, M., Nikolic, D., Banach, M., Patti, A.M., Montalto, G., Rizvi, A.A., Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr. Pharm. Des. 20:31 (2014), 4953–4960.
2. Hu, F.B., Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34:6 (2011), 1249–1257.
3. Rizzo, M., Avogaro, A., Montalto, G., Rizvi, A.A., Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opin. Ther. Targets 17:7 (2013), 739–742.
4. Rizvi, A.A., Patti, A.M., Giglio, R.V., Nikolic, D., Amato, A., Al-Busaidi, N. et al., Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert. Opin. Biol. Ther. 15:10 (2015), 1391–1397.
5. Rizzo, M., Abate, N., Chandalia, M., Rizvi, A.A., Giglio, R.V., Nikolic, D. et al., Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J. Clin. Endocrinol. Metab. 100:2 (2015), 603–606.
6. Rizzo, M., Rizvi, A.A., Patti, A.M., Nikolic, D., Giglio, R.V., Castellino, G. et al., Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc. Diabetol., 15(1), 2016, 162.
7. Adeghate, E., Medicinal chemistry of novel anti-diabetic drugs. Open Med. Chem. J. 5:Suppl. 2 (2011), 68–69.
8. Okerson, T., Chilton, R.J., The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc. Ther. 30:3 (2012), e146–55.
9. Stonehouse, A., Okerson, T., Kendall, D., Maggs, D., Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr. Diabetes Rev. 4:2 (2008), 101–109.
10. Meier, J.J., Rosenstock, J., Hincelin-Mery, A., Roy-Duval, C., Delfolie, A., Coester, H.V. et al., Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 38:7 (2015), 1263–1273.
11. Lovshin, J.A., Glucagon-like peptide-1 receptor agonists: a class update for treating type 2 diabetes. Can. J. Diabetes 41:5 (2017), 524–535.
12. Schnell, O., Ryden, L., Standl, E., Ceriello, A., Group CES, Updates on cardiovascular outcome trials in diabetes. Cardiovasc. Diabetol., 16(1), 2017, 128.
13. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A. et al., Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375:4 (2016), 311–322.
14. O'Neil, P.M., Garvey, W.T., Gonzalez-Campoy, J.M., Mora, P., Ortiz, R.V., Guerrero, G. et al., Effects of liraglutide 3.0 mg on weight and risk factors in Hispanic versus non-Hispanic populations: subgroup analysis from scale randomized trials. Endocr. Pract. 22:11 (2016), 1277–1287.
15. Herzlinger, S., Horton, E.S., Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. Diabetes Res. Clin. Pract. 100:1 (2013), 1–10.
16. Rizzo, M., Chandalia, M., Patti, A.M., Di Bartolo, V., Rizvi, A.A., Montalto, G. et al., Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc. Diabetol., 13, 2014, 49.
17. Masmiquel, L., Leiter, L.A., Vidal, J., Bain, S., Petrie, J., Franek, E. et al., LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc. Diabetol., 15, 2016, 29.
18. Mancini, M.C., de Melo, M.E., The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetol. Metab. Syndr., 9, 2017, 44.
19. Chaudhuri, A., Ghanim, H., Vora, M., Sia, C.L., Korzeniewski, K., Dhindsa, S. et al., Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97:1 (2012), 198–207.
20. Zhang, J.Y., Wang, X.Y., Wang, X., Effects of liraglutide on hemodynamic parameters in patients with heart failure. Oncotarget 8:37 (2017), 62693–62702.
21. Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R.S., Nielsen, R., Hanselmann, A. et al., Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur. J. Heart Fail. 19:1 (2017), 69–77.
22. Margulies, K.B., Hernandez, A.F., Redfield, M.M., Givertz, M.M., Oliveira, G.H., Cole, R. et al., Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316:5 (2016), 500–508.
23. Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L.P., Bouchelouche, K., Sorensen, J. et al., Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: a double-blind, randomized, placebo-controlled LIVE sub-study. J. Nucl. Cardiol., 2017, 10.1007/s12350-017-1000-2.
24. Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M. et al., The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. Cardiovasc. Diabetol., 16(1), 2017, 122.
25. Marfella, R., Sardu, C., Calabro, P., Siniscalchi, M., Minicucci, F., Signoriello, G. et al., Non-ST-Elevation Myocardial Infarction (NSTEMI) outcome in type 2 diabetic patients with non-obstructive coronary artery stenosis: effects of incretin treatment. Diabetes Obes. Metab. 20:3 (2017), 723–729.
26. Rizzo, M., Nikolic, D., Banach, M., Giglio, R.V., Patti, A.M., Di Bartolo, V. et al., The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective. J. Clin. Lipidol. 8:2 (2013), 173–181.
27. Kistorp, C., Holmager, P., Rasmussen, J., Schou, M., Faber, J., Tarnow, L. et al., The effect of liraglutide on body composition among patients with heart failure with and without type 2 diabetes: a sub-study from the LIVE randomised clinical trial. Diabetologia, 59(Suppl. 1), 2016, 367.
28. Gaspari, T., Welungoda, I., Widdop, R.E., Simpson, R.W., Dear, A.E., The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(−/−) mouse model. Diab. Vasc. Dis. Res. 10:4 (2013), 353–360.
29. Moretto, T.J., Milton, D.R., Ridge, T.D., Macconell, L.A., Okerson, T., Wolka, A.M. et al., Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 30:8 (2008), 1448–1460.
30. Zinman, B., Hoogwerf, B.J., Duran Garcia, S., Milton, D.R., Giaconia, J.M., Kim, D.D. et al., The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 146:7 (2007), 477–485.
31. DeFronzo, R.A., Triplitt, C., Qu, Y., Lewis, M.S., Maggs, D., Glass, L.C., Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 33:5 (2010), 951–957.
32. Kadowaki, T., Namba, M., Imaoka, T., Yamamura, A., Goto, W., Boardman, M.K. et al., Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J. Diabetes Investig. 2:3 (2011), 210–217.
33. Buse, J.B., Bergenstal, R.M., Glass, L.C., Heilmann, C.R., Lewis, M.S., Kwan, A.Y. et al., Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154:2 (2011), 103–112.
34. Holman, R.R., Bethel, M.A., Mentz, R.J., Thompson, V.P., Lokhnygina, Y., Buse, J.B. et al., Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377:13 (2017), 1228–1239.
35. Torimoto, K., Okada, Y., Mori, H., Otsuka, T., Kawaguchi, M., Matsuda, M. et al., Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc. Diabetol., 14, 2015, 25.
36. DeYoung, M.B., MacConell, L., Sarin, V., Trautmann, M., Herbert, P., Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol. Ther. 13:11 (2011), 1145–1154.
37. Grimm, M., Han, J., Weaver, C., Griffin, P., Schulteis, C.T., Dong, H. et al., Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Postgrad. Med. 125:3 (2013), 47–57.
38. Diamant, M., Van Gaal, L., Guerci, B., Stranks, S., Han, J., Malloy, J. et al., Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2:6 (2014), 464–473.
39. Bhushan, R., Elkind-Hirsch, K.E., Bhushan, M., Butler, W.J., Duncan, K., Marrioneaux, O., Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes Technol. Ther. 11:6 (2009), 353–359.
40. Henry, R.R., Rosenstock, J., Logan, D., Alessi, T., Luskey, K., Baron, M.A., Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J. Diabetes Complicat. 28:3 (2014), 393–398.
41. Whitson, A., Azeem, R., Alessi, T., Baron, M.A.I.T.C.A., 650 provides a novel therapeutic approach to treating patients with type 2 diabetes. Diabetologia, 59(Suppl. 1), 2016, 362.
42. Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes. Available from: https://www.prnewswire.com/news-releases/intarcia-announces-successful-cardiovascular-safety-results-in-phase-3-freedom-cvo-trial-for-itca-650-an-investigational-therapy-for-type-2-diabetes-300264245.html, 2016.
43. Sorli, C., Harashima, S.-I., Tsoukas, G., Unger, J., Derving Karsbøl, J., Hansen, T. et al., Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1). Diabetologia, 59(Suppl. 1), 2016, 364.
44. Ahrén, B., Masmiquel Comas, L., Kumar, H., Sargin, M., Derving Karsbøl, J., Hald Jacobsen, S. et al., Efficacy and safety of once-weekly semaglutide vs sitagliptin as addon to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2). Diabetologia, 59(Suppl. 1), 2016, 365.
45. Ahmann, A.J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I. et al., Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 41:2 (2018), 258–266.
46. Davies, M., Pieber, T.R., Hartoft-Nielsen, M.L., Hansen, O.K.H., Jabbour, S., Rosenstock, J., Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318:15 (2017), 1460–1470.
47. Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A. et al., Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375:19 (2016), 1834–1844.
48. Skydsgaard, N., Novo Plans Larger Study After Encouraging Semaglutide Results. Available from: https://www.reuters.com/article/us-health-diabetes-novo-nordisk-idUSKCN11M0F6, 2016.
49. Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V. et al., Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373:23 (2015), 2247–2257.
50. Bentley-Lewis, R., Aguilar, D., Riddle, M.C., Claggett, B., Diaz, R., Dickstein, K. et al., Rationale, design, and baseline characteristics in evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am. Heart J. 169:5 (2015), 631–638 (e7).
51. Forst, T., Pfutzner, A., Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. Expert. Opin. Pharmacother. 14:16 (2013), 2281–2296.
52. Hanefeld, M., Raccah, D., Monnier, L., Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opin. Drug Metab. Toxicol., 2016, 1–11.
53. Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R.T., Botros, F.T., Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab. Res. Rev. 32:8 (2016), 776–790.
54. Wysham, C., Guerci, B., D'Alessio, D., Jia, N., Botros, F.T., Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diabetes Obes. Metab. 18:11 (2016), 1138–1142.
55. Ferdinand, K.C., Botros, F.T., Atisso, C.M., Sager, P.T., Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc. Diabetol., 15, 2016, 38.
56. Dungan, K.M., Povedano, S.T., Forst, T., Gonzalez, J.G., Atisso, C., Sealls, W. et al., Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384:9951 (2014), 1349–1357.
57. Bethel, M.A., Patel, R.A., Merrill, P., Lokhnygina, Y., Buse, J.B., Mentz, R.J. et al., Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 6:2 (2017), 105–113.
58. Bush, M.A., Matthews, J.E., De Boever, E.H., Dobbins, R.L., Hodge, R.J., Walker, S.E. et al., Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes. Metab. 11:5 (2009), 498–505.
59. Rendell, M.S., Albiglutide: a unique GLP-1 receptor agonist. Expert. Opin. Biol. Ther. 16:12 (2016), 1557–1569.
60. Tanzeum (albiglutide) Discontinued After FDA Warns of Risk of Anaphylaxis Reaction. Available from: https://trulaw.com/fda/tanzeum-albiglutide-anaphylaxis-reaction/.
61. ANZEUM (albiglutide) Discontinuation — Q&A. Available from: https://www.tanzeum.com/pdfs/consumer-faq.pdf, 2018.
62. Nauck, M.A., Meier, J.J., Cavender, M.A., Abd El Aziz, M., Drucker, D.J., Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136:9 (2017), 849–870.
63. Fala, L., Tanzeum (Albiglutide): a once-weekly GLP-1 receptor agonist subcutaneous injection approved for the treatment of patients with type 2 diabetes. Am. Health Drug Benefits 8:Spec Feature (2015), 126–130.
64. Schnell, O., Ryden, L., Standl, E., Ceriello, A., Group CES, Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc. Diabetol., 15(1), 2016, 139.
65. Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., Cariou, B., Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial. Diabetes Care 39:9 (2016), 1501–1509.
66. Pareek, M., Bhatt, D.L., Oral antidiabetic agents and cardiovascular outcomes. Curr. Probl. Cardiol. 43:3 (2017), 111–126.
67. Mutie, P.M., Giordano, G.N., Franks, P.W., Lifestyle precision medicine: the next generation in type 2 diabetes prevention?. BMC Med., 15(1), 2017, 171.
68. Scirica, B.M., Bhatt, D.L., Braunwald, E., Raz, I., Cavender, M.A., Im, K. et al., Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 1:9 (2016), 989–998.
69. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S. et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373:22 (2015), 2117–2128.
70. Standl, E., Schnell, O., McGuire, D.K., Ceriello, A., Ryden, L., Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol. 5:5 (2017), 391–402.
71. Orgaard, A., Holst, J.J., The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. Diabetologia 60:9 (2017), 1731–1739.
72. Cooper, L.L., Palmisano, J.N., Benjamin, E.J., Larson, M.G., Vasan, R.S., Mitchell, G.F. et al., Microvascular function contributes to the relation between aortic stiffness and cardiovascular events: the Framingham heart study. Circ. Cardiovasc. Imaging, 9(12), 2016.
73. Stefanadis, C., Antoniou, C.K., Tsiachris, D., Pietri, P., Coronary atherosclerotic vulnerable plaque: current perspectives. J. Am. Heart Assoc., 6(3), 2017.
74. Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M. et al., A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 54 (2014), 19–26.
75. Song, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y. et al., Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 diabetes mellitus: a meta-analysis. Sci. Rep., 5, 2015, 10202.
76. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A. et al., Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375:4 (2016), 311–322.
77. Baggio, L.L., Yusta, B., Mulvihill, E.E., Cao, X., Streutker, C.J., Butany, J. et al., GLP-1 receptor expression within the human heart. Endocrinology 159:4 (2018), 1570–1584.
78. Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojevic, S. et al., Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J. Mol. Cell. Cardiol. 89:Pt B (2015), 365–375.
79. Costantino, S., Paneni, F., Battista, R., Castello, L., Capretti, G., Chiandotto, S. et al., Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels. Diabetes 66:9 (2017), 2472–2482.
80. Chen, C., Khismatullin, D.B., Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells. PLoS One, 10(3), 2015, e0123088.
81. Nikolic, D., Giglio, R.V., Patti, A.M., Castellino, G., Li Volti, G., Montalto, G. et al., The reduction in small dense low-density lipoproteins by liraglutide is independently associated with reduced carotid atherosclerosis in patients with type-2 diabetes. Diabetologia 59:Suppl. 1 (2016), S99–S100.
82. Engelbrechtsen, L., Lundgren, J., Wewer Albrechtsen, N.J., Mahendran, Y., Iepsen, E.W., Finocchietto, P. et al., Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obes. Sci. Pract. 3:4 (2017), 425–433.
83. Moss, J.W., Ramji, D.P., Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets. Future Med. Chem. 8:11 (2016), 1317–1330.